February 19, 2018 / 7:36 AM / 7 months ago

BRIEF-Oasmia Pharma says all patients have been treated in two ongoing studies with Docecal

Feb 19 (Reuters) - Oasmia Pharmaceutical AB:

* REG-OASMIA PHARMACEUTICAL’S DOCECAL PROGRAM ACHIEVES SIGNIFICANT DEVELOPMENT MILESTONE

* SAYS ‍ANNOUNCES THAT ALL PATIENTS HAVE BEEN TREATED IN TWO ONGOING STUDIES WITH DOCECAL IN METASTATIC BREAST CANCER

* SAYS THE WORK TO COMPILE THE RESULTS IS ONGOING

* SAYS POSITIVE RESULTS FROM THE STUDY PROGRAM WILL BE SUFFICIENT TO APPLY FOR SALES- AND MARKETING APPROVAL IN RUSSIA, WHICH IS ONE OF THE WORLD’S FASTEST GROWING ONCOLOGY MARKETS

* OASMIA PLANS TO SUBMIT FOR APPROVAL DURING THE SECOND HALF OF 2018

* INTENDS TO INITIATE DISCUSSIONS REGARDING POSSIBLE REGISTRATION OF DOCECAL BASED ON THE CURRENT PROGRAM WITH EMA FOR THE EU AND WITH THE FDA FOR THE USA​ Source text for Eikon: Further company coverage: (Stockholm Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below